Preconditioning of the Tumor Vasculature and Tumor Cells by Intermittent Hypoxia: Implications for Anticancer Therapies

Philipppe Martinive,1 Florence Defresne,1 Caroline Bouzin,1 Julie Saliez,1 Florence Lair,1 Vincent Grégoire,1 Carine Michiels,1 Chantal Dessy,1 and Olivier Feron1

1Unit of Pharmacology and Therapeutics (FATH 5349), Université Catholique de Louvain (UCL); 2Center for Molecular Imaging and Experimental Radiotherapy, Brussels, Belgium; and 3Laboratory of Biochemistry and Cellular Biology, University of Namur, Namur, Belgium

Abstract

Hypoxia is a common feature in tumors associated with an increased resistance of tumor cells to therapies. In addition to O2 diffusion–limited hypoxia, another form of tumor hypoxia characterized by fluctuating changes in pO2 within the disorganized tumor vascular network is described. Here, we postulated that this form of intermittent hypoxia promotes endothelial cell survival, thereby extending the concept of hypoxia-driven resistance to the tumor vasculature. We found that endothelial cell exposure to cycles of hypoxia reoxygenation not only rendered them resistant to proapoptotic stresses, including serum deprivation and radiotherapy, but also increased their capacity to migrate and organize in tubes. By contrast, prolonged hypoxia failed to exert protective effects and even seemed deleterious when combined with radiotherapy. The use of hypoxia-inducible factor-1α (HIF-1α)–targeting small interfering RNA led us to document that the accumulation of HIF-1α during intermittent hypoxia accounted for the higher resistance of endothelial cells. We also used an in vivo approach to enforce intermittent hypoxia in tumor-bearing mice and found that it was associated with less radiation-induced apoptosis within both the vascular and the tumor cell compartments (versus normoxia or prolonged hypoxia). Radioresistance was further ascertained by an increased rate of tumor regrowth in irradiated mice preexposed to intermittent hypoxia and confirmed in vitro using distinctly radiosensitive tumor cell lines. In conclusion, we have documented that intermittent hypoxia may condition endothelial cells and tumor cells in such a way that they are more resistant to apoptosis and more prone to participate in tumor progression. Our observations also underscore the potential of drugs targeting HIF-1α to sensitize the tumor vasculature to anticancer treatments. (Cancer Res 2006; 66(24): 11736–44)

Introduction

Tumor hypoxia may account for resistance to conventional anticancer modalities and is therefore generally associated with bad prognosis (1, 2). Commonly described in tumors, chronic hypoxia refers to the imbalance between O2 delivery and O2 consumption (3). Although the high metabolic rate of proliferating tumor cells easily justifies the consumption arm, the sources of chronic deficiencies in tumor O2 supply are multiple. Diffusion distance from the tumor vasculature, flow resistance, or progressive longitudinal hemoglobin saturation may, for instance, compromise homogenous O2 delivery to the whole tumor (4). The disorganized tumor neovasculature, however, is generally claimed as the common denominator of the above causes of deficit in O2 supply. Yet, this view underestimates the temporal dimension according to which these defects may be valid at a given time but not at another one. Indeed, angiogenesis is a dynamic process constantly remodeling the tumor vasculature (5) that per se combat the major cause of its induction (e.g., hypoxia). Also, the more mature tumor vascular compartment, i.e., arterioles, may be subject to vasomotion that also modulates tumor blood flow (6–8). In addition to the alterations in vessel conductance properties, microregional blood instabilities, and in particular alterations in RBC distribution within the vascular trees and partitioning at bifurcations (9–13), may account for or aggravate the transient reduction in pO2. Altogether, these observations suggest that acute or intermittent hypoxia is a ubiquitous process occurring within most solid tumors (7, 14–16). Periodicities from minutes to days have been identified in mice, rats, and nonrodent species (11–13, 16–20), underlying the many overlapping sources of temporal frequencies of fluctuation in tumor oxygenation (4, 21).

The major phenotypic shift associated with chronic hypoxia is tumor cell resistance to chemotherapy and radiotherapy (14, 22–24) and more invasive and metastatic features (25, 26). Recently, intermittent hypoxia was similarly proposed to favor tumor cell dissemination (27, 28). Still, one obvious difference between chronic and intermittent hypoxia has thus far been largely neglected. The tumor vasculature should be largely influenced by the latter, more precisely by the acute episodes of deep hypoxia. Hence, endothelial cells at the interface between blood and tumor cells are influenced by instabilities in RBC flux, vasomotion, or vascular remodeling, even independently of blood stasis phenomena (29, 30). The possible influence of intermittent hypoxia on the phenotype of endothelial cells lining tumor blood vessels may have significant therapeutic implications. Cyclic hypoxia may, for instance, permit resistance to treatment and thereby affects the survival of hundreds of tumor cells (proportionally dependent on a few vascular endothelial cells).

To explore this concept, we have “preconditioned” endothelial cell to intermittent or prolonged hypoxia and evaluated their resistance to serum deprivation and radiotherapy, as well as their capacity to participate in angiogenesis. We have paradoxically identified the hypoxia-induced factor-1α (HIF-1α; despite the interrupting reoxygenation phases) as a key mediator of the intermittent hypoxia-induced phenotypic shift. Finally, we have...
validated in vivo, in tumor-bearing mice, the intermittent hypoxia-mediated protection against radiotherapy-induced apoptosis and extended the paradigm of intermittent hypoxia-induced cell survival to the tumor cell compartment.

Materials and Methods

Cell culture. Transplantable liver tumor (TLT) cells, fibrosarcoma (Fss1), and melanoma (B16-F10) cells were routinely cultured in 175-mm flask in serum-containing DMEM. For terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay, cells were seeded into 16-well Labtek (NUNC, Naperville, IL) and grown to confluence. Human umbilical vein endothelial and bovine aortic endothelial cells were routinely cultured in 60-mm dishes in endothelial growth medium (Clonetics, Walkersville, MD). Two hours before starting the survival experiments, cells were serum starved; for long-term survival studies, culture medium was resupplemented with serum. To reach and control hypoxia conditions, cells were placed in a modular incubator chamber (Billups Rothenberg, Inc., Del Mar, CA) and flushed for 10 minutes with a gas mixture of 5% CO2-95% N2; the final medium pO2 value was consistently measured below the 0.5% to 1% range. The chamber was then sealed and placed at 37°C in conventional cell incubator.

Mouse model. Male NMRI mice (Elevage Janvier, Le Genest-St-Isle, France) were used in experiments with syngeneic TLT liver tumor carcinoma cells (31). Mice received an i.m. injection of 105 tumor cells in the posterior right leg. The tumor diameters were tracked with an electronic caliper. When the tumor diameter reached 4.0 ± 0.5 mm, mice were randomly assigned to a treatment group. Unanesthetized mice were placed in a Plexiglas box and exposed to a continuous flow of air or of a defined O2-N2-CO2 gas mixture as previously described by Cairns et al. (27,28); intermittent hypoxia preconditioning on tumor growth following the reoxygenation after the last cycle of intermittent hypoxia or after noninterrupted (prolonged) hypoxia on the ability of endothelial cells to resist proapoptotic stresses, such as serum deprivation and low-dose radiotherapy. Of note, radiotherapy (2 Gy) was always administered in normoxic conditions, i.e., following 1 hour of reoxygenation. One-hour hypoxia was sufficient to reach a robust expression of HIF-1α in cultured endothelial cells (Fig. 1A). The reoxygenation phase caused a rapid abrogation of the induced HIF-1α expression (Fig. 1B). Based on these time courses and in accordance with previous measurements by our group of fluctuations in the tumor vasculature occurring at the frequency of 0.5 to 1 cycle per hour (36, 37), we chose to explore the influence of intermittent hypoxia on endothelial cell biology by using a scheme protocol of three cycles of 1-hour hypoxia interrupted by 30-minute periods of reoxygenation.

We first compared the influence of intermittent hypoxia and noninterrupted (prolonged) hypoxia on the ability of endothelial cells to resist proapoptotic stresses, such as serum deprivation and low-dose radiotherapy. Of note, radiotherapy (2 Gy) was always administered in normoxic conditions, i.e., following 1 hour of reoxygenation after the last cycle of intermittent hypoxia or after the end of prolonged hypoxia. Clonogenic assays done on serum-deprived endothelial cell revealed that, whereas the prolonged hypoxic conditions time-dependently reduced cell survival, intermittent hypoxia promoted endothelial cells survival (Fig. 1C). When compared with cells maintained in normoxia, even more cells resist serum deprivation when first exposed to intermittent hypoxia (Fig. 1C). Figure 1D documents that, similarly, intermittent but not prolonged hypoxia preconditioning reduced endothelial cell death in response to 2 Gy ionizing radiations.

To further determine whether the spared endothelial cells following radiotherapy had acquired a specific phenotype, we used two assays aiming to evaluate the capacity of endothelial cells to migrate (see Fig. 2A) and to organize in tubes when cultured on Matrigel (see Fig. 2B). We found that endothelial cells preexposed to intermittent hypoxia and consecutively to ionizing radiations had a higher angiogenic capacity: both migration (Fig. 2A and C) and tube formation (Fig. 2B and D) were increased by ~3-fold (versus nonirradiated, normoxia-exposed endothelial cells). Radiotherapy per se increased the angiogenic index values (see Fig. 2C and D, respectively).
third columns), confirming previous results from our group (32). The combination with the intermittent hypoxia prechallenge was found synergistic; intermittent hypoxia alone had no significant effects. Importantly, 3-hour prolonged hypoxia did not reveal any potentiating proangiogenic effects of radiotherapy (not shown).

**HIF-1α mediates the intermittent hypoxia-associated preconditioning effects.** Next, we examined whether the transcription factor HIF-1α was involved in mediating the phenotypic shift induced by intermittent hypoxia in endothelial cells. We first evaluated the abundance of HIF-1α protein at different times within the hypoxia-reoxygenation protocol. Figure 3A reveals that the expression level of the transcription factor was higher after each new cycle of hypoxia (see also Fig. 3B for quantitative data). We also observed that when the HIF-1α induction was blocked by specific silencing siRNA (see Fig. 3F), the protection conferred by intermittent hypoxia against serum deprivation (Fig. 3C) and radiotherapy (Fig. 3D) was lost. Two different siRNAs were used with similar results (see Fig. 3C) and transfection with a HIF-1α–encoding plasmid enabled to prevent the siRNA effects (Fig. 3E), further validating the HIF-1α dependence of the intermittent hypoxia-protective effects. Figure 3F documents the efficacy of the procedure of siRNA cell transduction, leading to a >90% abrogation of HIF-1α expression and the compensatory recombinant expression of HIF-1α.

**Intermittent hypoxia influences the survival of both vascular and tumor cells in vivo.** To verify whether intermittent hypoxia could account for in vivo tumor vascular endothelial cell resistance to radiotherapy, we designed experiments where tumor-bearing mice were exposed, before the administration of radiotherapy (10 Gy), to either normal air or 7% O₂ for 3 hours or three cycles of 1-hour 7% O₂ breathing interrupted by 30-minute periods of normal air breathing. The 7% O₂ breathing conditions were previously shown by others (27, 28) and confirmed by us in preliminary studies to lead to a tumor pO₂ strictly <3 mm Hg. Also, mice were allowed to breathe normal air for 1 hour before radiotherapy to avoid confounding effects of remaining local O₂ deprivation; restoration of normal pO₂ levels was verified using the electron paramagnetic resonance technology (not shown). TUNEL assays were done on tumors collected from mice submitted to the above experimental conditions. CD31 costaining was used to determine the extent of TUNEL-positive vascular structures (see Fig. 4A). Figure 4B shows that intermittent hypoxia reduced by ~2-fold (P < 0.01) the extent of TUNEL-positive vascular structures, whereas prolonged hypoxia had the opposite effects.
significantly increasing the extent of apoptosis within the tumor vasculature (+ ~75% over normoxic values; P < 0.01).

Interestingly, the above observations could be extended to the surrounding tumor tissue. We compared the extent of radiation-induced TUNEL-positive cells into the whole tumor after the different enforced hypoxia prechallenges described above. As depicted in Fig. 5A, intermittent hypoxia reduced the extent of radiotherapy-induced apoptosis of tumor cells. Because of the heterogeneous distribution of TUNEL-positive cells (presence of apoptotic hotspots) within the tumor, a scoring procedure was used to quantify these observations. Figure 5B confirms a dramatic shift to the left (toward the low-score apoptosis levels) in the intermittent hypoxia conditions (P < 0.01). Of note, in the above in vivo experiments, prolonged hypoxia (3 hours) did not promote tumor cell survival; a trend toward more apoptosis was even observed when compared with tumor-bearing mice maintained in normoxia (not shown).

We also evaluated the tumor growth delay in irradiated tumor-bearing mice prechallenged or not by the three cycles of 1 hour 7% O2 breathing. Figure 5C showed that the intermittent hypoxia preconditioning led to a higher tumor resistance to radiotherapy (versus normoxic conditions), in good agreement with the lesser apoptosis levels reported in Fig. 5A. Finally, to determine the effects of intermittent hypoxia on the intrinsic sensitivity of tumor cells versus the combined effects on both vascular and tumor cells, we repeated these experiments using cultured tumor cells. Figure 5D shows that the protective effects of intermittent hypoxia on radiation-induced apoptosis were confirmed in vitro.

**Figure 2.** Intermittent hypoxia promotes endothelial cell migration and tube formation. Representative pictures of migrating endothelial cell in the ‘wound assay’ (A) and endothelial cell network (tube) formation on Matrigel (B); experiments were carried out with cells maintained in normoxia or after challenging the cells with intermittent hypoxia (three cycles of 1-hour hypoxia interrupted by 30-minute reoxygenation) and radiotherapy (Rad.; 2 Gy). Quantification is provided as a migration index (C) and a tube formation index (D), respectively (see Materials and Methods); the extents of migration and tube formation after intermittent hypoxia or radiotherapy alone are also provided. **. P < 0.01 (n = 3); ns, nonsignificant.
Figure 3. HIF-1α mediates the prosurvival effects of intermittent hypoxia. A, representative HIF-1α immunoblots from endothelial cells collected before and at the end of each of the three cycles of 1-hour hypoxia; β-actin immunoblots (used for normalization) are also provided. B, the accumulation of HIF-1α during each consecutive hypoxia cycle. **, $P < 0.01$ ($n = 4$). C, D, and E, the effects of HIF-1α siRNA transduction on the clonogenic survival of endothelial cells maintained in normoxia or exposed to the intermittent hypoxia protocol described above. The effects of serum deprivation (C), exposure to 2 Gy radiation (D), and concomitant recombinant (rec.) HIF-1α expression (E). Two different siRNAs, named a and b (see Materials and Methods for exact sequences), were used in (C). Columns, % survival of endothelial cells maintained in normoxia; bars, SE. *, $P < 0.05$; **, $P < 0.01$; ns, nonsignificant ($n = 3–5$). F, representative HIF-1α immunoblot from endothelial cells exposed to normoxia or intermittent hypoxia, after HIF-1α siRNA and/or HIF-1α–expressing plasmid transduction.
Interestingly, melanoma B16 and fibrosarcoma FsaII cells (more and less radiosensitive than transplantable liver hepatocarcinoma cells, respectively) revealed a similar increased resistance to radiotherapy when first preexposed to intermittent hypoxia.

Discussion

A major finding of this study is that intermittent hypoxia preconditions endothelial cells in such a way that they become more resistant to stress than cells exposed to prolonged hypoxia or even maintained in normoxia. Intermittent hypoxia is nowadays recognized as a hallmark of many tumors as acknowledged by a variety of approaches, including mismatch staining (14, 38), oxygen-sensing microelectrodes (16), intravitral microscopy (39), or more recently magnetic resonance imaging (19, 37). It has now become evident that tumor hypoxia is not simply a phenomenon alternating with normoxia depending on the angiogenic status of the tumors (8, 40). Intermittent hypoxia, also known as acute or cyclic hypoxia, may result from the transient occlusion of blood vessels and, more generally, from temporal instabilities in RBC flux (4, 7). These microregional blood instabilities may directly arise from disproportionate cell partitioning at capillary bifurcations but also from more dynamic processes like arteriolar vasomotion and vascular remodeling (see Introduction). Investigations on the relevance of intermittent hypoxia already led to the identification of a more invasive phenotype of tumor cells (27, 28). Here, we provide evidence that intermittent hypoxia also participates in the tumor resistance to radiotherapy and, importantly, that a part of these effects proceeds through endothelial cells lining tumor blood vessels. These cells are usually described as genetically stable and thereby do not lead, as reported for tumor cells, to the clonal selection of cells more adapted to apoptosis. However, the principle of intermittent hypoxia has introduced the concept that vascular cells, although directly located at the interface with the bloodstream, may also be exposed to a hypoxic environment (thus far reserved to tumor cells at a certain distance from tumor blood vessels).

The resistance to proapoptotic serum deprivation and radiotherapy was substantiated by using clonogenic assays that integrate the cell death occurring after several cell divisions. Furthermore, promigratory and proangiogenic properties were also conferred to endothelial cells by intermittent hypoxia. The effects of intermittent hypoxia reinforce the angiogenic potential of endothelial cells surviving ionizing radiations (32). By exposing animals bearing tumors to cycles of hypoxia reoxygenation, we further found a net lower rate of apoptotic nuclei in vascular structures (versus mice maintained in a normoxic atmosphere or prolonged hypoxia). Altogether, these data emphasize the link between intermittent hypoxia and resistance to antitumor treatments through the preservation (or lesser alteration) of the tumor vascular compartment. Importantly, we have also found that intermittent hypoxia protected tumor cells against irradiation-induced cell death (see Fig. 5). This was verified in vivo by documenting a higher postradiation rate of tumor growth in mice preexposed to intermittent hypoxia but also in vitro using three tumor cell lines with distinct intrinsic radiosensitivity. These data extend the paradigm of intermittent hypoxia as a trigger of prosurvival pathways to both endothelial cells and tumor cells.
Figure 5. Intermittent hypoxia promotes tumor cell radioresistance both in vitro and in vivo. TLT liver tumor–bearing mice were either maintained in normoxia or exposed to the intermittent hypoxia protocol described in Fig. 4 legend. One hour after the last hypoxia cycle, mice were locally irradiated (10 Gy). Tumors were either collected 24 hours later to evaluate apoptosis on cryosections or measured daily to evaluate tumor growth delay. A, representative pictures of TUNEL-positive (pink) tumor cell nuclei (from mice maintained in normoxia or preexposed to intermittent hypoxia); the tumor sections were also counterstained with DAPI (blue). B, the extent of irradiation-induced TUNEL-positive apoptotic tumor cells (CD31-costained cells were excluded from the counting procedure), evaluated by a scoring procedure to integrate the variability of the pattern observed in a maximum of tumor cryoslices (80–100 high-magnification fields evaluated by two blinded investigators). Columns, % of high-magnification fields [where the indicated score was attributed from 0 (no or very few apoptotic nuclei) to 3 (>50% apoptotic nuclei)]; bars, SE. The extent of apoptosis is significantly higher in cells not preconditioned by intermittent hypoxia (IH; ■) or maintained in normoxia (○); tumor growth in untreated mice (○; n = 8). C, tumor growth delay when radiotherapy (10 Gy) is administered to mice prechallenged by intermittent hypoxia (IH; ■) or maintained in normoxia (○); tumor growth in untreated mice (○; n = 8). D, the radiosensitivity of cultured tumor cells [transplantable liver tumor (TLT) hepatocarcinoma, FsaII fibrosarcoma, and B16 melanoma] was also examined in vitro after exposure to the intermittent hypoxia protocol described in Fig. 3. One hour after the last hypoxia cycle, tumor cells were irradiated (10 Gy) and analyzed 24 hours later by TUNEL assay. Columns, number of irradiation-induced TUNEL-positive nuclei per high-magnification fields; bars, SE. *, P < 0.05; **, P < 0.01 (n = 4; 10 high-magnification fields were considered per experiment).
with the caveat that increased endothelial cell death also indirectly alters the tumor cell survival.

A second key finding of the current study is the involvement of HIF-1α in mediating the pro-survival effects of the intermittent hypoxia preconditioning. We first documented that HIF-1α progressively accumulates with the number of cycles of hypoxia (see Fig. 3A). Whether this is due to a lack of induction of prolyl hydroxylase domain proteins, as observed with prolonged hypoxia (41), or is due to another stabilizing mechanism is currently under investigation. Nevertheless, the role of HIF-1α was ascertained by the ability of specific siRNA to prevent the protective effects of intermittent hypoxia versus serum deprivation and low-dose radiotherapy (and by the capability of recombinant HIF-1α to reverse the siRNA effects; see Fig. 3E). Transcriptomic studies are ongoing in our laboratory to identify downstream targets within the many genes with hypoxia-responsive elements containing promoters (42). Of note, two major angiogenic axes, namely those dependent on vascular endothelial growth factor and basic fibroblast growth factor, are, however, likely not involved in the observed HIF-1α-driven survival because we failed to detect significant changes in the transcript expression of these growth factors and their receptors (not shown).

Although drugs targeting HIF-1α, including strategies based on the siRNA technology (43), are currently developed to block the various adaptive processes induced by hypoxia or oncogenes in tumor cells (44), our data extend their therapeutic potential to the tumor vasculature compartment. Our study indicates that HIF-1α siRNA, despite having no effect on the survival of endothelial cells maintained in normoxia, reduced the intermittent hypoxia-driven cell survival to a lower level than that of cells maintained in normoxia (see Fig. 3C). When combined to radiotherapy, the HIF-1α siRNA also reduced cell survival to a larger extent than radiotherapy alone (see Fig. 3D). These observations indicate that if the HIF-1α induction is prevented, deleterious effects of intermittent hypoxia are unmasked. This is yet more relevant in the context of radiotherapy because HIF-1α was recently shown to be induced in response to the radiation exposure (45).

In conclusion, this study unravels the influence of intermittent hypoxia on the phenotype of the tumor vasculature. Cyclic modifications of tumor $pO_2$ may be considered together with the hypoxia-driven clonal selection of apoptosis-resistant cells as a source of resistance to conventional anticancer therapies. Although the nature of the transcriptomic changes within the tumor vasculature in response to repeated changes in tumor oxygenation warrants further investigation, this process was found to be largely HIF-1α dependent. Together with the observation that intermittent hypoxia promotes the survival not only of endothelial cells but also of tumor cells, our findings provide a new rationale to use HIF-1α-targeting drugs as an adjuvant modality to conventional radiotherapy and chemotherapy.

Acknowledgments

Received 6/5/2006; revised 10/11/2006; accepted 10/19/2006.

Grant support: The Fonds de la Recherche Scientifique, the Fonds de la Recherche Scientifique Médicale, the Fonds National de la Recherche Scientifique, the Télèvée, the Belgian Federation against Cancer, the J. Maisin Foundation, and an Action de Recherche Concertée (ARC 04/09-317) from the Communauté Française de Belgique.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References

Preconditioning of the Tumor Vasculature and Tumor Cells by Intermittent Hypoxia: Implications for Anticancer Therapies

Philippe Martinive, Florence Defresne, Caroline Bouzin, et al.


Updated version  Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/66/24/11736

Cited articles This article cites 42 articles, 13 of which you can access for free at: http://cancerres.aacrjournals.org/content/66/24/11736.full#ref-list-1

Citing articles This article has been cited by 15 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/66/24/11736.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/66/24/11736. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.